Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23724061 | 1.00 | LTA4H (0.87) | LTA4HPTGS1PTGS2PSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL3997911 | 0.98 | LTA4H (0.84) | LTA4HPTGS1PTGS2PSMB1PSMB5 | |
| SCHEMBL56495 | 0.98 | LTA4H (0.90) | LTA4HPTGS1PTGS2PSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL15254264 | 0.96 | LTA4H (0.87) | LTA4HPTGS1PTGS2PSMB1PSMB5 | |
| SCHEMBL4465869 | 0.91 | HRH3 (0.75) | LTA4HPTGS1PTGS2HRH3KCNH2 | |
| SCHEMBL2968936 | 0.91 | HRH3 (0.75) | LTA4HPTGS1PTGS2HRH3KCNH2 | |
| SCHEMBL4993214 | 0.90 | HRH3 (0.73) | LTA4HPTGS1PTGS2HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL736843 | 0.90 | HRH3 (0.73) | LTA4HPTGS1PTGS2HRH3KCNH2 | |
| SCHEMBL4457910 | 0.89 | LTA4H (0.76) | LTA4HPTGS1PTGS2HRH3KCNH2 | |
| SCHEMBL3398830 | 0.89 | LTA4H (0.75) | LTA4HPTGS1PTGS2PSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57188567-A | — | — | None | — | — | JP | disclosed |
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4100400-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | Kings College London (GB) | 2022-12-14 | — | — | EP | disclosed |
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2021156636-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021017384-A1 | DIHYDRO-PYRROLO-PYRIMIDINE SELECTIVE JAK2 INHIBITOR | 上海勋和医药科技有限公司 | 2021-02-04 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10683282-B2 | Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-06-16 | — | — | US | disclosed |
| US-10683282-B2 | Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-06-16 | — | — | US | disclosed |
| US-20190315726-A1 | MULTI-SUBSTITUTED PYRIMIDINE DERIVATIVES WITH EXCELLENT KINASE INHIBITORY ACTIVITIES | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-10-17 | — | — | US | disclosed |
| US-20030130165-A1 | Method for treating neurodegenerative disorders | REITZ ALLEN B (US) | 2003-07-10 | — | — | US | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| US-6441049-B2 | Method of treating neurodegenerative disorders via inhibition of amyloid beta peptide binding | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013374-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS VIA INHIBITION OF AMYLOID BETA PEPTIDE BINDING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
| EP-1100779-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2001-05-23 | — | — | EP | disclosed |
| EP-1083889-A2 | METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062505-A2 | METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062882-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-09 | — | — | WO | disclosed |
| JP-S57188567-A | NOVEL PREPARATION OF ETOMIDOLINE | FUJIMOTO SEIYAKU KK | 1982-11-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683282-B2 | Multi-substituted pyrimidine derivatives with excellent kinase inhibitory activities | JAK1, NUAK1, JAK2 | LTA4H 4416/4885PTGS1 1472/4885PTGS2 3096/4885 |
| US-20020013374-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS VIA INHIBITION OF AMYLOID BETA PEPTIDE BINDING | ACHE, CHRNA7, APP | LTA4H 1944/4885PTGS1 3840/4885PTGS2 4056/4885 |
| US-20240246920-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | RIF1, NAT1, POLR1C | LTA4H 2619/4885PTGS1 2856/4885PTGS2 4083/4885 |
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | JAK2, JAK1, JAK3 | LTA4H 3498/4885PTGS1 776/4885PTGS2 611/4885 |
| US-20190315726-A1 | MULTI-SUBSTITUTED PYRIMIDINE DERIVATIVES WITH EXCELLENT KINASE INHIBITORY ACTIVITIES | JAK1, NUAK1, JAK2 | LTA4H 4416/4885PTGS1 1472/4885PTGS2 3096/4885 |
| US-20030130165-A1 | Method for treating neurodegenerative disorders | ACHE, CHRNA7, PARK7 | LTA4H 970/4885PTGS1 2735/4885PTGS2 2741/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LTA4H 1373/4885PTGS1 1996/4885PTGS2 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.